Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Issue 5 (6th January 2014)

• Record Type: Journal Article
• Authors: Fransen, Marlene; Agaliotis, Maria; Nairn, Lillias; Votrubec, Milana; Bridgett, Lisa; Su, Steve; Jan, Stephen; March, Lyn; Edmonds, John; Norton, Robyn; Woodward, Mark; Day, Richard
• Other Names: Buckland-Wright Chris collab.; Bridges-Webb Charles collab.; Heritier Stephane collab.; Jones Graeme collab.; Sambrook Phillip collab.; Speechly Catherine collab.; Vignon Eric collab.; Jovanovic Gorica collab.; Jeram Shila collab.; Dowd Mitchell collab.; Champion Mandy collab.; Grealy Sarah collab.; Watson Deanne collab.; Vrataric Anton collab.; Johnson Cecil collab.; White Rose collab.; O'Connell Paul collab.; Milwraith Fay collab.; Kennedy Danielle collab.; Faulkes Christine collab.; Bulton Olivia collab.; Johnson Kathleen collab.
• Is Part Of: Annals of the rheumatic diseases. Volume 74:Issue 5(2015)
• Page Start: 851
• Page End: 858
• Publication Date: 2014-01-06
• Subjects: osteoarthritis knee -- glucosamine -- chondroitin -- pain -- disease progression; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-203954
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To determine if the dietary supplements, glucosamine and/or chondroitin, result in reduced joint space narrowing (JSN) and pain among people with symptomatic knee osteoarthritis. Methods: A double-blind randomised placebo-controlled clinical trial with 2-year follow-up. 605 participants, aged 45–75 years, reporting chronic knee pain and with evidence of medial tibio-femoral compartment narrowing (but retaining >2 mm medial joint space width) were randomised to once daily: glucosamine sulfate 1500 mg (n=152), chondroitin sulfate 800 mg (n=151), both dietary supplements (n=151) or matching placebo capsules (n=151). JSN (mm) over 2 years was measured from digitised knee radiographs. Maximum knee pain (0–10) was self-reported in a participant diary for 7 days every 2 months over 1 year. Results: After adjusting for factors associated with structural disease progression (gender, body mass index (BMI), baseline structural disease severity and Heberden's nodes), allocation to the dietary supplement combination (glucosamine–chondroitin) resulted in a statistically significant (p=0.046) reduction of 2-year JSN compared to placebo: mean difference 0.10 mm (95% CI 0.002 mm to 0.20 mm); no significant structural effect for the single treatment allocations was detected. All four allocation groups demonstrated reduced knee pain over the first year, but no significant between-group differences (p=0.93) were detected. 34 (6%) participants reported possibly-related adverse medical events over the 2-year follow-up period. Conclusions: Allocation to the glucosamine–chondroitin combination resulted in a statistically significant reduction in JSN at 2 years. While all allocation groups demonstrated reduced knee pain over the study period, none of the treatment allocation groups demonstrated significant symptomatic benefit above placebo. Trial Registration ClinicalTrials.gov identifier: NCT00513422; http://www.clinicaltrials.gov